Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $735.39, giving the company a market capitalization of 77.99B. It carries a P/E multiple of 17.87 and pays a dividend yield of 47.5%.
On 2026-01-31, Regeneron(REGN) stock moved within a range of $728.00 to $774.37. With shares now at $735.39, the stock is trading +1.0% above its intraday low and -5.0% below the session's peak.
Trading activity shows a volume of 1.32M, compared to an average daily volume of 939.9K.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
REGN News
Raymond James analyst Christopher Raymond maintained a Buy rating on Regeneron today and set a price target of $870.00. Claim 50% Off TipRanks Premium Unlock he...
Raymond James raised the firm’s price target on Regeneron (REGN) to $870 from $820 and keeps an Outperform rating on the shares. While most major contributors t...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported fourth-quarter adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consen...
Analyst ratings
70%
of 30 ratingsMore REGN News
Image source: The Motley Fool. Jan. 30, 2026, 8:30 a.m. ET Call participants President and Chief Executive Officer — Dr. Leonard Schleifer Board Co-Chair, Pres...
Regeneron stock slipped early Friday after the biotech behemoth reported adjusted earnings of $11.44 per share on $3.88 billion in fourth-quarter sales. Analyst...
Reports Q4 revenue $3.9B, consensus $3.79B. “Regeneron (REGN) performed well in 2025, with financial strength driven by our four blockbuster medicines and futur...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will release earnings results for its fourth quarter, before the opening bell on Friday, Jan. 30. Analysts expect...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.